Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Autologous anti-HLA-A2/NY-ESO-1 TCR T cells |
Synonyms | |
Therapy Description |
Autologous anti-HLA-A2/NY-ESO-1 TCR T cells are T-lymphocytes engineered to express a T-cell receptor (TCR) targeting HLA-A2/NY-ESO-1 expressed on tumor cells, which potentially induce killing of tumor cells expressing NY-ESO-1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autologous anti-HLA-A2/NY-ESO-1 TCR T cells | A2-ESO-1 TCR-T cells | Autologous anti-HLA-A2/NY-ESO-1 TCR T cells are T-lymphocytes engineered to express a T-cell receptor (TCR) targeting HLA-A2/NY-ESO-1 expressed on tumor cells, which potentially induce killing of tumor cells expressing NY-ESO-1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05989828 | Phase I | Cyclophosphamide + Fludarabine Autologous anti-HLA-A2/NY-ESO-1 TCR T cells | A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |